PHM — Pharma Mar SA Income Statement
0.000.00%
Last trade - 00:00
- €670.32m
- €550.05m
- €158.15m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 85.8 | 270 | 230 | 196 | 158 |
Cost of Revenue | |||||
Gross Profit | 80.6 | 256 | 213 | 183 | 149 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 103 | 114 | 137 | 152 | 162 |
Operating Profit | -17.5 | 156 | 92.4 | 44.1 | -3.83 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -21.7 | 146 | 95.1 | 43.8 | -3.62 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.18 | 137 | 92.9 | 49.4 | 1.14 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -11.4 | 137 | 92.9 | 49.4 | 1.14 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.4 | 137 | 92.9 | 49.4 | 1.14 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.495 | 7.52 | 5.12 | 2.8 | 0.06 |
Dividends per Share |